title: Trends in diagnostic and therapeutic criteria in Graves' disease in the last 10 years.
abstract: A questionnaire describing a typical clinical case of Graves' disease and 10 variations on it was mailed to 70 Spanish units of endocrinology with the aim of assessing the new diagnostic and therapeutic trends for hyperthyroidism caused by Graves' disease in Spain and to compare the results obtained from previous studies carried out in Europe and Spain 10 years previously. Responses indicated that thyrotrophin (98%) and free thyroxine (88%) were the most used tests in the in vitro diagnosis of Graves' disease with a significant decrease in the use of total thyroxine, total triiodothyronine, and thyroglobulin in comparison with the surveys conducted 10 years previously in Europe and Spain. The presence of antibodies against the thyrotrophin receptor was the most frequently used immune marker in the diagnosis (78%) and the new use of antithyroperoxidase antibodies (36%) in diagnosis is noteworthy. Antithyroid drugs remain the treatment of choice (98%). Surgery was used mainly for large size goitres (33%) and radioiodine for recurrences after medical (61%) or surgical (80%) treatment. In conclusion, the responses obtained from this questionnaire provide insight into current specialist diagnostic and therapeutic practices with respect to Graves' disease and which could be of value to non-specialist units of endocrinology.
authors.affiliation: Endocrinology and Clinical Nutrition Service, Department of Medicine, University Hospital San Cecilio, Granada, Spain. amalia@goliat.ugr.es
authors.forename: F
authors.initials: F
authors.lastname: Escobar-Jiménez
authors.forename: M L
authors.initials: ML
authors.lastname: Férnandez-Soto
authors.forename: V
authors.initials: V
authors.lastname: Luna-López
authors.forename: M
authors.initials: M
authors.lastname: Quesada-Charneco
authors.forename: D
authors.initials: D
authors.lastname: Glinoer
mesh_terms: D013956:Antithyroid Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D004704:Endocrinology / Q000639:trends*; D006111:Graves Disease / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007453:Iodide Peroxidase / Q000276:immunology; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D011989:Receptors, Thyrotropin / Q000276:immunology; D012008:Recurrence; D013030:Spain; D011795:Surveys and Questionnaires; D013960:Thyroid Function Tests / Q000639:trends; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood
chemical_list: D013956:Antithyroid Agents; D001323:Autoantibodies; D015415:Biomarkers; D007457:Iodine Radioisotopes; D011989:Receptors, Thyrotropin; D013972:Thyrotropin; D007453:Iodide Peroxidase; D013974:Thyroxine